BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Nesina (Alogliptin) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Nesina (Alogliptin)\, from ClinicalTrials
 .gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07093476-299@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nesina (Alogliptin): Phase 3 readout est. (NCT07093476)
DESCRIPTION:Nesina (Alogliptin)\, phase 3\, Type 2 Diabetes.\nStudy: Effica
 cy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2
  Diabetes on a Background of Alogliptin and Metformin\nEstimated primary c
 ompletion: December 2026. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/alogliptin#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07093476
URL:https://assetmemo.bio/drug/alogliptin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07289750-299@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Nesina (Alogliptin): Phase 4 readout est. (NCT07289750)
DESCRIPTION:Nesina (Alogliptin)\, phase 4\, Type 2 Diabetes.\nStudy: The Ef
 fect of Alogliptin Combined With Actoplus Met on Glucose and Lipid Metabol
 ism and Pancreatic Function in Patients With T2DM Complicated With MAFLD\n
 Estimated primary completion: 31 August 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/alogliptin#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07289750
URL:https://assetmemo.bio/drug/alogliptin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
